These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 19429730)
41. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. Nguyen PL; Chen MH; Hoffman KE; Chen RC; Hu JC; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV BJU Int; 2012 Jul; 110(2):201-5. PubMed ID: 22085233 [TBL] [Abstract][Full Text] [Related]
42. Prostate cancer: epidemiology and health-related quality of life. Penson DF; Rossignol M; Sartor AO; Scardino PT; Abenhaim LL Urology; 2008 Dec; 72(6 Suppl):S3-11. PubMed ID: 19095126 [TBL] [Abstract][Full Text] [Related]
43. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study. Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991 [TBL] [Abstract][Full Text] [Related]
44. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732 [TBL] [Abstract][Full Text] [Related]
45. Predicting life expectancy in men with clinically localized prostate cancer. Cowen ME; Halasyamani LK; Kattan MW J Urol; 2006 Jan; 175(1):99-103. PubMed ID: 16406881 [TBL] [Abstract][Full Text] [Related]
46. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720 [TBL] [Abstract][Full Text] [Related]
47. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. Tewari A; Johnson CC; Divine G; Crawford ED; Gamito EJ; Demers R; Menon M J Urol; 2004 Apr; 171(4):1513-9. PubMed ID: 15017210 [TBL] [Abstract][Full Text] [Related]
48. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648 [TBL] [Abstract][Full Text] [Related]
49. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study. van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199 [TBL] [Abstract][Full Text] [Related]
50. Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study. Mohan R; Beydoun HA; Beydoun MA; Barnes-Eley M; Davis J; Lance R; Schellhammer P Qual Life Res; 2011 Jun; 20(5):713-21. PubMed ID: 21132389 [TBL] [Abstract][Full Text] [Related]
51. Counterpoint: prostate cancer life expectancy can not be accurately predicted from currently available tools. McCloskey SA; Kuettel MR J Natl Compr Canc Netw; 2007 Aug; 5(7):709-13. PubMed ID: 17692176 [TBL] [Abstract][Full Text] [Related]
52. Sex or survival: trade-offs between quality and quantity of life. Singer PA; Tasch ES; Stocking C; Rubin S; Siegler M; Weichselbaum R J Clin Oncol; 1991 Feb; 9(2):328-34. PubMed ID: 1988579 [TBL] [Abstract][Full Text] [Related]
53. Limitations of the National Comprehensive Cancer Network Daskivich TJ; Wood LN; Skarecky D; Ahlering T; Freedland S J Urol; 2017 Feb; 197(2):356-362. PubMed ID: 27582436 [TBL] [Abstract][Full Text] [Related]
54. Management of Prostate Cancer in the Elderly. Tay KJ; Moul JW; Armstrong AJ Clin Geriatr Med; 2016 Feb; 32(1):113-32. PubMed ID: 26614864 [TBL] [Abstract][Full Text] [Related]
55. Patient expectations of benefit from systemic treatments for metastatic prostate cancer. Oswald LB; Kasimer R; Rappazzo K; Fought AJ; Penson DF; Morgans AK Cancer Med; 2020 Feb; 9(3):980-987. PubMed ID: 31840434 [TBL] [Abstract][Full Text] [Related]
56. Point: the value of predicting life expectancy in men with clinically localized prostate cancer. Clayton DB; Urban DA J Natl Compr Canc Netw; 2007 Aug; 5(7):703-8. PubMed ID: 17692175 [TBL] [Abstract][Full Text] [Related]
57. [Treatment with curative intention of prostate cancer depending on age and life expectancy]. Ojea Calvo A Med Clin (Barc); 2005 Jun; 125(4):140-2. PubMed ID: 15989855 [No Abstract] [Full Text] [Related]
58. Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer. Beydoun HA; Mohan R; Beydoun MA; Davis J; Lance R; Schellhammer P BJU Int; 2010 Aug; 106(3):334-41. PubMed ID: 20151969 [TBL] [Abstract][Full Text] [Related]
59. Estimating patient health in prostate cancer treatment counseling. Chesnut GT; Tin AL; Fleshner KA; Benfante NE; Vickers AJ; Eastham JA; Sjoberg DD; Carlsson SV Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):271-275. PubMed ID: 34732855 [TBL] [Abstract][Full Text] [Related]
60. Re: The impact of co-morbidity on life expectancy among men with localized prostate cancer. Newschaffer CJ J Urol; 1997 Mar; 157(3):964-5. PubMed ID: 9072623 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]